# Spatial profiling of longitudinal glioblastoma reveals consistent changes in cellular architecture, post-treatment

## TL;DR

This study uses advanced imaging to track how the cellular makeup of glioblastoma tumors changes before and after treatment, revealing patterns that may help prevent cancer recurrence.

## Contribution

The study reveals treatment-induced spatial reorganization of the glioblastoma tumor microenvironment using imaging mass cytometry.

## Key findings

- Post-treatment, normal brain cells increase while vascular cells decrease.
- Cellular interactions among astrocytes, oligodendrocytes, and vascular cells increase after treatment.
- The tumor microenvironment shifts from hypoxia-driven layers to organization driven by reactive astrocytes and lymphocytes.

## Abstract

Glioblastoma (GBM), the most aggressive adult brain cancer, comprises a complex tumor microenvironment (TME) with diverse cellular interactions that drive progression and pathobiology. The aim of this study was to understand how these spatial patterns and interactions evolve with treatment.

To explore these relationships, we employed imaging mass cytometry to measure the expression of 34 protein markers, enabling the identification of GBM-specific cell types and their interactions at the single-cell protein level in paired primary (pre-treatment) and recurrent (post-treatment) GBM samples from five patients.

We find a significant post-treatment increase in normal brain cells alongside a reduction in vascular cells. Moreover, despite minimal overall change in cellular diversity, interactions among astrocytes, oligodendrocytes, and vascular cells increase post-treatment, suggesting reorganization of the TME. The GBM TME cells form spatially organized layers driven by hypoxia pre-treatment, but this influence diminishes post-treatment, giving way to less organized layers with organization driven by reactive astrocytes and lymphocytes.

These findings provide insight into treatment-induced shifts in GBM’s cellular landscape, highlighting aspects of the evolving TME that appear to facilitate recurrence and are, therefore, potential therapeutic targets.